Abstract
Genomic surveillance of SARS-CoV-2 has been essential to provide an evidence base for public health decisions throughout the SARS-CoV-2 pandemic. Sequencing data from clinical cases has provided data crucial to understanding disease transmission and the detection, surveillance, and containment of outbreaks of novel variants, which continue to pose fresh challenges. However, genomic wastewater surveillance can provide important complementary information by providing estimates of variant frequencies which do not suffer from sampling bias, and capturing all variants circulating in a population. Here we show that genomic SARS-CoV-2 wastewater surveillance can detect fine-scale differences within urban centres, specifically within the city of Liverpool, UK, during the emergence of Alpha and Delta variants between November 2020 and June 2021. Overall, the correspondence between wastewater and clinical variant frequencies demonstrates the reliability of wastewater surveillance. Yet, discrepancies between the two approaches when the Alpha variant was first detected emphasises that wastewater monitoring can also capture missing information resulting from asymptomatic cases or communities less engaged with testing programmes, as found by a simultaneous surge testing effort across the city.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.protocols.io/view/wastewater-sequencing-using-the-easyseq-rc-pcr-sar-bx6dpra6
Funding Statement
Funding was provided by NERC (NE/V003860/1) and DHSC UK (2020_097). COG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) [grant code:MC_PC_19027], and Genome Research Limited, operating as the Wellcome Sanger Institute.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Use of surplus nucleic acid derived from routine diagnostics and associated patient data was approved through the COG-UK consortium by the Public Health England Research Ethics and Governance Group (R&D NR0195).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵9 https://www.cogconsortium.uk, Full list of consortium names and affiliations are in the appendix
Data Availability
Wastewater sequencing data will be deposited and publicly available on the European Nucleotide Archive by 1st July 2022. The clinical case data used in this study is visualised at https://www.cogconsortium.uk/tools-analysis/public-data-analysis-2/. A filtered, privacy conserving version of the lineage-LTLA-week dataset is publicly available online (https://covid19.sanger.ac.uk/downloads) and gives access to almost all used data, despite a small number of cells having been suppressed to conserve patient privacy.
